{"id":304444,"created_at":"2024-01-03 11:15:53","updated_at":"2024-05-28 13:23:19","deleted_at":null,"published_at":"2024-01-03 11:15:53","original_id":null,"artist_id":148994,"title":"Weight loss Ozempic injections (0.25mg, 0.5mg, & 1g) for sale in Berlin Germany","slug":"weight-loss-ozempic-injections-025mg-05mg-1g-for-sale-in-berlin-germany","status":"published","description":null,"album_id":null,"streets":1,"source_type":"s3","source":"file","lyrics":"Contact our company manager on WhatsApp +12816065109 or \r\nEmail. DATOMMY454@GMAIL.COM\r\nWHATSAPP message +12816065109 European and UK Regulators Investigate Suicide Risk With Ozempic and Similar Drugs Buy on WhatsApp only WhatsApp message +12816065109 Regulators in Europe and the UK are investigating cases of suicidal thoughts reported in some people who were taking Ozempic and several similar drugs for type 2 diabetes and weight loss.\r\nThe European Medicines Agency (EMA) is reviewing \u201cthe risk of suicidal thoughts and thoughts of self-harm\u201d with several drugs in a family of medicines used for weight loss and type 2 diabetes known as GLP-1 receptor agonists, including Ozempic (semaglutide), Saxenda (liraglutide), and Wegovy (semaglutide). Regulators are investigating about 150 possible cases of self-injury and suicidal thoughts connected to these medicines, EMA said in a\u00a0statement\u00a0issued July 11.\r\n\r\nIn the UK, the medicines and healthcare products regulatory agency MHRA has launched a similar investigation, according to a July 26 report by Reuters. British regulators are looking at drugs involved in the EMA investigation, as well as the GLP-1 drugs Bydureon (exenatide), Lyxumia (lixisenatide), and Trulicity (dulaglutide), Reuters reported.\r\n\u201cI think it is appropriate that there is additional oversight to the use of these medications, especially as they expand into broader public use and misuse,\u201d says Beverly Tchang, MD, an assistant professor of clinical medicine at Cornell University in Ithaca, New York, who treats patients with obesity and type 2 diabetes at at Weill Cornell Medicine in New York City.\r\n\r\nOzempic and Wegovy Remain in Short Supply in the U.S.\r\n\r\n Contact our company manager on WhatsApp +12816065109 or \r\nEmail. DATOMMY454@GMAIL.COM\r\n\r\nTwo GLP-1 drugs containing the active ingredient semaglutide, the type 2 diabetes drug Ozempic and the weight loss medicine Wegovy, have been in short supply domestically for many months now. The shortages are being driven in large part by the growing number of people without obesity or diabetes who want these medicines to help them lose weight, Dr. Tchang says.\r\nTwo GLP-1 drugs approved by the U.S. Food and Drug Administration (FDA) for weight loss \u2014 Wegovy and Saxenda \u2014 already carry warnings about suicidal behavior and thoughts.\r\n\u201cThe labeling recommends that patients treated with these medications be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and any unusual changes in mood or behavior; to discontinue these medications in patients who experience suicidal thoughts or behaviors; and to avoid these medications in patients with a history of suicidal attempts or active suicidal ideation,\u201d the FDA said in a statement to Everyday Health.\r\nMOST HELPFUL\r\nFDA Approves Diabetes Drug Mounjaro for Weight Loss Under New Name: Zepbound\r\nPrescription Weight Loss Drugs: Zepbound and Mounjaro, Ozempic and Wegovy, Saxenda, and Others\r\nMounjaro Shows Potential as Next Blockbuster Obesity Drug in Late-Stage Trial\r\nFDA Says There\u2019s No Risk of Suicidal Thoughts With Ozempic\r\nContact our company manager on WhatsApp +12816065109 or \r\nEmail. DATOMMY454@GMAIL.COM\r\n\r\nOzempic, which is FDA-approved only for type 2 diabetes, carries no such warning. The FDA said that \u201cclinical trial data did not support a warning and precaution for suicidal ideation or behavior for the GLP-1 receptor agonists approved for diabetes indications.\u201d\r\n\r\nOverall, however, the FDA said GLP-1 drugs are safe. \u201cWe continue to conclude that the benefits of these medications outweigh their risks when they are used according to the FDA-approved labeling,\u201d the FDA said.\r\nUnlike in the United States, GLP-1 drugs in Europe and the UK don\u2019t already carry warnings about suicidal thoughts or behaviors. Because there already are warnings on some GLP-1 drugs in the United States, an FDA investigation into this side effect is unlikely, says Joshua Zeichner, MD, an associate professor of dermatology at Mount Sinai Hospital in New York City who helps patients manage skin side effects from Ozempic.\r\n\r\nIt\u2019s also possible that European regulators are investigating the suicide risk of GLP-1 drugs because of a totally different type of weight loss medicine, Acomplia (rimonabant), was pulled from the market in 2008 over serious psychiatric side effects, Tchang says. This drug was never approved in the United States.\r\nIs It Worth It to Take Ozempic or Wegovy?\r\n\r\n Contact our company manager on WhatsApp +12816065109 or \r\nEmail. DATOMMY454@GMAIL.COM\r\nFor now, the best course of action for patients is to take medicines prescribed by their doctors as directed, Dr. Zeichner says. \u201cAll medications come with potential side effects,\u201d Zeichner adds. \u201cHowever, if their overall benefit outweighs the risk of developing one of those side effects or the impact of one of those side effects, then the medication is worth taking.\u201d\r\nWhen it comes specifically to psychiatric side effects, patients should take the warnings about the risk of suicidal thoughts and behavior seriously, Tchang says. \u201cPatients should discuss any mood changes they have with their doctor,\u201d Tchang advises. \u201cRegardless of whether they are taking a GLP-1 or not, they should always seek help if they have thoughts about harming themselves.\u201d Contact our company manager on WhatsApp +12816065109 or \r\nEmail. DATOMMY454@GMAIL.COM","download_count":12,"play_count":2,"restrict_download":0,"generated_thumbnail":null,"flag_count":0,"download_count_24":1,"download_count_24_at":"2024-05-28","reupload_sent":0,"thumb_path":"https:\/\/s3.eu-central-1.amazonaws.com\/sol-assets\/uploads\/public\/659\/525\/7ed\/thumb_996461_300_300_0_0_crop.jpeg","status_reason":"published","status_reason_alt":null,"tags":[]}